About Us

Problems We Are Solving

The genomics revolution has created a data tsunami. We have developed a novel approach for managing Immuno-Oncology clinical trials and translational research. Our software suite is solving the following problems.

  • Difficulties in correlating clinical data and exploratory data
  • Problems related to understanding the MOA for new clinical trial candidates
  • Issues related to proper monitoring of the subject’s health during a clinical trial
  • Roadblocks in the analysis of diverse multi-omics and clinical datasets that prevent investigators in gathering predictive insights
Problems Thumbs

Vision

“Our vision is to provide an innovative platform to help you find the right medicine for the right patients at the right time, regionally and globally. We are looking for a few good men and women across different disciplines who have passion for this mission and take great pride in building game-changing products and solutions for cancer patients around the world and who believe in our principles”

Mission

“Our mission is to be the technology catalyst to enable our collaborators/customers to find a cure for cancer, COVID-19 and rare orphan diseases.  It is our firm belief that the intersection of innovations in technology, science and business is the only way to fight deadly disease.”

Board of Directors and Advisors

John Dean

Managing Partner, Startup Capital VC

Mohan Uttarwar

Chief Executive Officer, iNDX.Ai

Dr. Arun Jamkar

Chief Medical Officer

Dr. Gowhar Shafi

VP, Computational Biology & Translational Research

Deelip Mhaske

Business Advisor

Dr Richard Friedberg MD,PhD

President- College of American Pathologists (CAP)

Carol Berry MBA

Senior Vice-President and Chief Business Officer, Caprion

Prasun Mishra

Chief Executive Officer, Agility Pharmaceuticals

Dr Stefan Scherer

Global Head Experimental Medicine at GSK

Dr Rob Monroe MD PhD

Chief Medical Officer at Bio-Techne & Advanced Cell Diagnostics, Pathologist

Dr Darshan Gandhi MD

Oncology Physician, Texas Oncology-Methodist Charlton Cancer Center

Kelly Gordon, Ph.D., MB(ASCP)CM

Entrepreneur, Owner at Boudicca Dx., LLC

Dr Rupesh Chaturvedi

Biomedical researcher/ Innovator

Piyush Gupta

Advisor at Arka Venture Labs

Denis Coleman, PhD

Strategic Advisor, Startup Capital Venture

Hans-Burghardt Ziermann

Managing Partner at Mobil Consult GmbH

Damien Anthony Porter

Business Development Manager, iNDX.ai

Christopher Mattson

Business Development Manager, iNDX.ai

Quick Facts

Expertise

Expertise

Highly skilled employees in multidisciplinary teams

Global

Global

Offices in USA and India, Partnered with Avantor in Europe

Security

Security

Global Standards in Data Protection

Tracking Automation

Tracking Automation

Biospecimen workflow for efficient trial operations

Actionable biological insights

Actionable biological insights

Overcome insights missed by traditional bioinformatics tools.

Technology

Technology

Leveraging AI, ML and  NLP

OUR BROCHURE

View our 2019 Company brochure for an easy to read guide on our offered product.

DOWNLOAD

WHITE PAPER

Accelarating biomarker discovery in I/O using AI

DOWNLOAD

CASE STUDY

Collaborative case study for Academic centres

DOWNLOAD

Our Partners

AI-powered Life Science Analytics Cloud (LSAC) technology platform will empower researchers around the world to dynamically visualize, analyze, and interrogate data across all available programs. LSAC seamlessly integrates, curates, and animates clinical trial data, delivering more actionable insights for faster decision making. Additionally, Saama has already leveraged LSAC’s deep learning capabilities to enable queries of the COVID-19 Open Research Dataset (CORD-19), a publicly available database that contains more than 45,000 scholarly articles about COVID-19 and is intended to help the medical community keep up with the latest research and find the most accurate answers to questions related to the virus and its impact.

Has built a COVID-19 patient symptom survey with electronic health record (EHR) and device integration. Andaman7 is helping patients understand their COVID-19 risk through easy symptom tracking and information. The platform is HIPAA, GDPR, and 21CFRPart11 compliant, and is and available in 22 languages. Andaman7 enables proper privacy controls by patient via recurring consent, and offers the ability to collect patient reported, device and electronic medical record (EMR) data. Their advanced technology delivers information and guidance to patients, and provides access to over 10,000 clinics and hospital EMRs in the U.S.

Operates a global patient data network platform, Patient Network Explorer, which currently has near-real-time access to the EHR-based data of more than 27 million patients. The platform enables flexible queries of demographic data, diagnoses, medications and procedures, and laboratory results, and includes event-based and temporal constraint capabilities.

Clinerion supports research and real-world evidence (RWE) queries for COVID-19 cases, epidemiology, and health economics and outcomes research. Clinerion can track and analyze complex combinations of patient data, longitudinally, to understand patient treatment diagnostics, treatment modalities, co-morbidities and developing cohort and outcome models by country and health care institution. Clinerion works with its partners and hospital networks to support the community, enable patient outreach and facilitate longitudinal epidemiological studies.

(In partnership with Chrysalis Biomed Advisors) is a strategy consulting firm with focus on digital transformation of life sciences companies spanning large global corporations to startups, including pharmaceutical/biotechs, medtech, diagnostics, health information and IT player and healthcare providers.

Founded in 2005 and backed by Artiman Ventures and Sequoia Capital, Cellworks has built the world’s strongest trans-disciplinary team of molecular biologists, cellular pathway modelers, semiconductor engineers, and internet software architects working towards a common goal of fighting disease to improve the lives of patients. Cellworks’ areas of therapeutic focus are oncology, immunology, dermatology and infectious diseases. Cellworks’ mission is to serve patients through advances in precision medicine that significantly improve treatment success.

Strand Life Sciences: Strand Life Sciences is a clinical research and diagnostics company that combines a long track record in bioinformatics with cutting-edge laboratory assays and a vast hospital partner network to drive newer generations of patient care. Strand’s customers include global instrument, diagnostic and pharmaceutical companies. Strand is also a pioneer of genomic testing in India. Strand’s diagnostics menu makes it India’s leading integrated specialized diagnostics company, covering oncology, genetics, fertility, women’s health, infectious diseases and general wellness.

Our Membership

The American Association for Cancer Research (AACR) is the world’s oldest and largest professional association related to cancer research. Based in Philadelphia, the AACR focuses on all aspects of cancer research, including basic, clinical, and translational research into the etiology, prevention, diagnosis, and treatment of cancer. Founded in 1907 by 11 physicians and scientists, the organization now has more than 34,000 members in over 90 countries.

The American Society of Clinical Oncology (ASCO) is a professional organization
representing physicians of all oncology sub-specialties who care for people with cancer.
Founded in 1964 by Drs. Fred Ansfield, Harry Bisel, Herman Freckman, Arnoldus Goudsmit, Robert Talley, William Wilson, and Jane C. Wright, ASCO has nearly 45,000 members worldwide.

The Society for Immunotherapy of Cancer (SITC), previously known as The International Society for Biological Therapy of Cancer (iSBTc) is a professional society of influential scientists, academicians, researchers, clinicians, government representatives, and industry leaders from around the world dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy.